Considering the protective effect of exendin-4 against oxidative stress in spiral ganglion neurons

Document Type : Original Article


Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical Chongqing, China


Objective(s): The protection of spiral ganglion neurons (SGNs) is crucial for hearing loss. Exendin-4 has been shown to have neuroprotective effects in several neurological disorders. Therefore, this study aimed to investigate the effect of the glucagon-like protein-1 receptor (GLP-1R) agonist exendin-4 on kanamycin-induced injury in mouse SGNs in vitro.
Materials and Methods: In this study, GLP-1R expression in SGNs was verified by immunofluorescence and immunohistochemical staining. In vitro-cultured SGNs and the organ of Corti were exposed to kanamycin with or without exendin-4 treatment. The cell survival rate was measured using the cell counting kit-8 assay, and the damage to auditory nerve fibers (ANF) projecting radially from the SGNs was evaluated using immunofluorescence staining. Reactive oxygen species (ROS) content was determined by flow cytometry, and glutathione peroxidase (GSH-Px) content, superoxide dismutase (SOD) activity, and malondialdehyde (MDA) content were determined by spectrophotometry. Protein expression of nuclear factor erythroid-2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) was detected using western blotting.
Results: GLP-1R was expressed in SGNs. Treatment with 1 mM kanamycin for 24 hr induced SGN damage. Exendin-4 (100 nM) had a protective effect against kanamycin-induced SGN cell injury, improved cell survival rate, reduced nerve fiber injury, increased SOD activity and GSH-Px level, and reduced MDA and ROS contents. The Nrf2/HO-1 pathway was activated.
Conclusion: Exendin-4 alleviates oxidative damage and exerts neuroprotective effects in kanamycin-induced SGN injury through the Nrf2/HO-1 signaling pathway. Exendin-4 has the potential to prevent or treat hearing loss due to SGN damage.


Main Subjects

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet 2018; 392:1789–1858.
2. Bindu LH, Reddy PP. Genetics of aminoglycoside-induced and prelingual non-syndromic mitochondrial hearing impairment: A review. Int J Audiol 2008; 47:702–707.
3. Zeng FG, Rebscher S, Harrison W, Sun X, Fen H. Cochlear implants: system design, integration, and evaluation. IEEE Rev Biomed Eng 2008; 1:115–142.
4. Schvartz-Leyzac KC, Pfingst BE. Assessing the relationship between the electrically evoked compound action potential and speech recognition abilities in bilateral cochlear implant recipients. Ear Hear 2018; 39:344-358.
5. Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: A key modulator in neurodegenerative diseases. Molecules 2019; 24:1583-1603.
6. Fetoni AR, Paciello F, Rolesi R, Paludetti G, Troian D. Targeting dysregulation of redox homeostasis in noise-induced hearing loss: oxidative stress and ROS signaling. Free Radic Biol Med 2019; 135:46–59.
7. Henderson D, Bielefeld EC, Harris KC, Hu BH. The role of oxidative stress in noise-induced hearing loss. Ear Hear 2006; 27:1-19.
8. Bottger EC, Schacht J. The mitochondrion: A perpetrator of acquired hearing loss. Hear Res 2013; 303:12-19.
9. Tan WJ, Thorne PR, Vlajkovic SM. Characterisation of cochlear inflammation in mice following acute and chronic  noise exposure. Histochem Cell Biol 2016; 146:219-230.
10. Fetoni AR, Eramo SL, Paciello F, Rolesi R, Podda MV, Troiani D, et al. Curcuma longa (curcumin) decreases in vivo cisplatin-induced ototoxicity through  heme oxygenase-1 induction. Otol Neurotol 2014; 35:169-177.
11. Benkafadar N, Menardo J, Bourien J, Nouvian R, Francois F, Decaudin D, et al. Reversible p53 inhibition prevents cisplatin ototoxicity without blocking  chemotherapeutic efficacy. EMBO Mol Med 2017; 9:7-26.
12. Fujimoto C, Yamasoba T. Oxidative stresses and mitochondrial dysfunction in age-related hearing loss. Oxid Med Cell Longev 2014; 2014:582849-582855.
13. Alvarado JC, Fuentes-Santamaria V, Melgar-Rojas P, Valero ML, Gabaldon-Ull MC, Miller JM, et al. Synergistic effects of free radical scavengers and cochlear vasodilators: A new  otoprotective strategy for age-related hearing loss. Front Aging Neurosci 2015; 7:86-93.
14. Muller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019; 30:72–130.
15. Chen S, Zhou M, Sun J, Guo A, Fernando RL, Chen Y, et al. DPP-4 inhibitor improves learning and memory deficits and AD-like  neurodegeneration by modulating the GLP-1 signaling. Neuropharmacology 2019; 157:107668-107679.
16. Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation:  Implications for neurodegenerative disease treatment. Pharmacol Res 2022; 186:106550-.
17. Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X, et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in alzheimer’s disease. Mol Metab 2021; 47:101180-101194.
18. Li QX, Gao H, Guo Y-X, Wang B-Y, Hua R-X, Gao L, et al. GLP-1 and underlying beneficial actions in alzheimer’s disease, hypertension, and NASH. Front Endocrinol (Lausanne) 2021; 12:721198-721210.
19. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: An analysis of national  pharmaceutical sales data. Lancet Infect Dis 2014; 14:742-750.
20. Bas E, Van De Water TR, Gupta C, Dinh J, Vu L, Martinez-Soriano F, et al. Efficacy of three drugs for protecting against gentamicin-induced hair cell and  hearing losses. Br J Pharmacol 2012; 166:1888-904.
21. Chun KJ, Lee CH, Kim KW, Lee SM, Kim SY. Effects of androgen receptor inhibition on kanamycin-induced hearing loss in rats. Int J Mol Sci 2021; 22:5307-5319.
22. Deng L, Ding D, Su J, Manohar S, Salvi R. Salicylate selectively kills cochlear spiral ganglion neurons by paradoxically up-regulating superoxide. Neurotox Res 2013; 24:307–319.
23. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021; 46:101102-101128.
24. Gao K, Ding D, Sun H, Roth J, Salvi R. Kanamycin damages early postnatal, but not adult spiral ganglion neurons. Neurotox Res 2017; 32:603–613.
25. Khalifa O, Al-Akl NS, Errafii K, Arredouani A. Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. Sci Rep 2022; 12:2226-2239.
26. Zhang M, Wu Y, Gao R, Chen X, Chen R, Chen Z. Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer’s disease by suppressing NLRP2 activation in astrocytes. Mol Cell Endocrinol 2022; 542:111529.
27. Shan Y, Tan S, Lin Y, Liao S, Zhang B, Chen X, et al. The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J Neuroinflammation 2019; 16:242-262.
28. Ye B, Wang Q, Hu X, Shen Y, Fan C, Chen P, et al. Restoring autophagic flux attenuates cochlear spiral ganglion neuron degeneration by promoting TFEB nuclear translocation via inhibiting MTOR. Autophagy 2019; 15:998–1016.
29. Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and oxidative stress in diabetic kidney disease: The targets for SGLT2 inhibitors and GLP-1 receptor agonists. Int J Mol Sci 2021; 22:10822-10860.
30. Cai X, She M, Xu M, Chen H, Li J, Chen X, et al. GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction. Int J Biol Sci 2018; 14:1696–1708.
31. Li Y, Glotfelty EJ, Karlsson T, Fortuno LV, Harvey BK, Greig NH. The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular  models of neurodegeneration. J Neurochem 2021; 159:867–886.
32. Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res 2018; 1865:721–733.
33. Yu C, Xiao JH. The Keap1-Nrf2 system: A mediator between oxidative stress and aging. Oxid Med Cell Longev 2021; 2021:6635460-6635476.
34. Zhang Q, Liu J, Duan H, Li R, Peng W, Wu C. Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. J Adv Res 2021; 34:43–63.
35. Dang X, He B, Ning Q, Liu Y, Guo J, Niu G, et al. Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-kappaB pathways. Respir Res 2020; 21:95-106.
36. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic  AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987; 84:3434-3438.
37. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ, et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev 2021; 42:101–132.
38. DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, et al. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab 2014; 307:630–643.
39. Abdel-Latif RG, Heeba GH, Taye A, Khalifa MA. Lixisenatide ameliorates cerebral ischemia-reperfusion injury via GLP-1 receptor  dependent/independent pathways. Eur J Pharmacol 2018; 833:145–154.
40. Combs CK. Are GLP-1 receptor agonists useful against traumatic brain injury? J Neurochem 2015; 135:1059–1061.
41. Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X, et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer’s disease. Mol Metab 2021; 47:101180-101194.
42. Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, et al. GLP-1 receptor agonists for Parkinson’s disease. Cochrane Database Syst Rev 2020; 7:12990-13037.
43. Grieco M, Giorgi A, Gentile MC, d’Erme M, Morano S, Maras B, et al. Glucagon-like peptide-1: A focus on neurodegenerative diseases. Front Neurosci 2019; 13:1112-1119.
44. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric  inhibitory polypeptide in patients with chronic renal insufficiency and healthy  control subjects. Diabetes 2004; 53:654-662.
45. Ahn YJ, Shin HJ, Jeong EA, An HS, Lee JY, Jang HM, et al. Exendin-4 pretreatment attenuates kainic acid-induced hippocampal neuronal death. Cells 2021; 10:2527-2543.
46. Rocha-Ferreira E, Poupon L, Zelco A, Leverin AL, Nair S, Jonsdotter A, et al. Neuroprotective exendin-4 enhances hypothermia therapy in a model of  hypoxic-ischaemic encephalopathy. Brain 2018; 141:2925-2942.
47. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic  pathologies, and extends survival in a mouse model of Huntington’s disease. Diabetes 2009; 58:318-328.
48. Song X, Sun Y, Wang Z, Su Y, Wang Y, Wang X. Exendin-4 alleviates beta-Amyloid peptide toxicity via DAF-16 in a Caenorhabditis  elegans model of Alzheimer’s disease. Front Aging Neurosci 2022;14:955113.
49. Wang J, Ding D, Salvi RJ. Carboplatin-induced early cochlear lesion in chinchillas. Hear Res 2003;181:65-72.
50. Kong WJ, Yin ZD, Fan GR, Li D, Huang X. Time sequence of auditory nerve and spiral ganglion cell degeneration following  chronic kanamycin-induced deafness in the guinea pig. Brain Res 2010;1331:28-38.
51. Gao K, Ding D, Sun H, Roth J, Salvi R. Kanamycin Damages Early Postnatal, but Not Adult Spiral Ganglion Neurons. Neurotox Res 2017;32:603-613.
52. Mao H, Chen Y. Noise-induced hearing loss: Updates on molecular targets and potential interventions. Neural Plast 2021. 2021: p. 4784385.
53. Liu W, Xu L, Wang X, Zhang D, Sun G, Wang M, et al. PRDX1 activates autophagy via the PTEN-AKT signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage. Autophagy 2021; 17: 4159–4181.
54. Shi W, Hou X, Bao X, Hou W, Jiang X, Ma L, et al. Mechanism and protection of radiotherapy induced sensorineural hearing loss for head and neck cancer. Biomed Res Int 2021; 2021: 3548706.
55. Rivas-Chacon L, Martínez-Rodríguez S, Madrid-García R, Yanes-Díaz J, Riestra-Ayora JI, Sanz-Fernández R, et al. Role of oxidative stress in the senescence pattern of auditory cells in age-related hearing loss. Anti-oxidants (Basel) 2021; 10: 1497.
56. Chang Q, Cai H, Wei L, Lan R. Chitosan oligosaccharides alleviate acute heat stress-induced oxidative damage by activating ERK1/2-mediated HO-1 and GSH-Px gene expression in breast muscle of broilers. Poult Sci 2022; 101: 101515.
57. Wang F, Li R, Tu P, Chen J, Zeng K, Jiang Y. Total glycosides of Cistanche deserticola promote neurological function recovery  by inducing neurovascular regeneration via Nrf-2/Keap-1 pathway in MCAO/R rats. Front Pharmacol 2020; 11: 236.
58. Naraki K, Rezaee R, Karimi G. A review on the protective effects of naringenin against natural and chemical toxic agents. Phytother Res 2021; 35: 4075–4091.
59. Oh YS, Jun HS. Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci 2017; 19: 26.
60. Zahan MS, Hasan A, Rahman MH, Meem KN, Moni A, Hannan MA, et al. Protective effects of fucoidan against kidney diseases: Pharmacological insights  and future perspectives. Int J Biol Macromol 2022; 209: 2119–2129.